A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. [electronic resource]
Producer: 20090910Description: 741-8 p. digitalISSN:- 1365-2141
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- adverse effects
- Antibodies, Monoclonal, Murine-Derived
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Disease-Free Survival
- Female
- Follow-Up Studies
- Humans
- Lymphoma -- drug therapy
- Lymphoma, B-Cell, Marginal Zone -- drug therapy
- Lymphoproliferative Disorders -- drug therapy
- Male
- Middle Aged
- Prospective Studies
- Rituximab
- Survival Rate
- Vidarabine -- adverse effects
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.